155 related articles for article (PubMed ID: 26629279)
1. Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma.
Raedler L
Am Health Drug Benefits; 2015 Mar; 8(Spec Feature):135-40. PubMed ID: 26629279
[No Abstract] [Full Text] [Related]
2. Proteasome inhibitors in the treatment of B-cell malignancies.
Schenkein D
Clin Lymphoma; 2002 Jun; 3(1):49-55. PubMed ID: 12141956
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.
Kurtin S; Knop CS; Milliron T
J Adv Pract Oncol; 2012 Nov; 3(6):406-10. PubMed ID: 25031973
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.
Oriol A; Giraldo P; Kotsianidis I; Couturier C; Olie R; Angermund R; Corso A
Hematology; 2015 Aug; 20(7):405-9. PubMed ID: 25494809
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.
Stork M; Sevcikova S; Brozova L; Spicka I; Maisnar V; Minarik J; Jungova A; Gregora E; Velichova R; Hajek R; Jelinek T; Pour L
Neoplasma; 2020 Jan; 67(1):178-184. PubMed ID: 31829027
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
Goranov SE; Goranova-Marinova VS
Folia Med (Plovdiv); 2005; 47(3-4):11-9. PubMed ID: 16761388
[TBL] [Abstract][Full Text] [Related]
7. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.
McCormack PL
BioDrugs; 2015 Jun; 29(3):207-14. PubMed ID: 26115634
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
Cvek B; Dvorak Z
Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Martin P; Ruan J; Furman R; Rutherford S; Allan J; Chen Z; Huang X; DiLiberto M; Chen-Kiang S; Leonard JP
Leuk Lymphoma; 2019 Dec; 60(12):2917-2921. PubMed ID: 31120355
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in the treatment of cancer.
Roccaro AM; Vacca A; Ribatti D
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):397-403. PubMed ID: 18221049
[TBL] [Abstract][Full Text] [Related]
13. [Multiple myeloma cell line U266 apoptosis induced by velcade].
Chen LJ; Li JY; Qian SX; Zhu GR; Zheng WJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):696-9. PubMed ID: 16928302
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors.
Cvek B
Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
16. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib for the treatment of mantle cell lymphoma.
Kane RC; Dagher R; Farrell A; Ko CW; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5291-4. PubMed ID: 17875757
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Utecht KN; Kolesar J
Am J Health Syst Pharm; 2008 Jul; 65(13):1221-31. PubMed ID: 18574011
[TBL] [Abstract][Full Text] [Related]
19. Velcade combinations in mantle cell lymphoma: are we learning anything?
Rule S
Leuk Lymphoma; 2011 Apr; 52(4):545-7. PubMed ID: 21438822
[No Abstract] [Full Text] [Related]
20. Bortezomib: a proteasome inhibitor with an evolving role in select subtypes of B-cell non-Hodgkin's lymphoma.
Koprivnikar JL; Cheson BD
Future Oncol; 2012 Apr; 8(4):359-71. PubMed ID: 22515439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
